KUMAMOTO University

R

研究実績RESEARCH ACHIEVEMENTS

  1. 1 .

    Lavorgna A, Matsuoka M, Harhaj EW.

    A critical role for IL-17RB signaling in HTLV-1 tax-induced NF-κB activation and T-cell transformation.

    PLoS Pathog. 2014 Oct 23;10(10):e1004418. doi: 10.1371/journal.ppat.1004418. PMID: 25340344; PMCID: PMC4207800.

  2. 2 .

    Cook LB, Melamed A, Niederer H, Valganon M, Laydon D, Foroni L, Taylor GP, Matsuoka M, Bangham CR.

    The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma.

    Blood. 2014 Jun 19;123(25):3925-31. doi: 10.1182/blood-2014-02-553602. Epub 2014 Apr 15. PMID: 24735963; PMCID: PMC4064332.

  3. 3 .

    Hiramoto N, Kurosawa S, Tajima K, Okinaka K, Tada K, Kobayashi Y, Shinohara A, Inoue Y, Ueda R, Tanaka T, Kim SW, Yamashita T, Heike Y, Fukuda T.

    Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients.

    Eur J Haematol. 2014 Feb;92(2):137-46. doi: 10.1111/ejh.12214. Epub 2013 Nov 9. PMID: 24127668.

  4. 4 .

    Zhao T, Satou Y, Matsuoka M.

    Development of T cell lymphoma in HTLV-1 bZIP factor and Tax double transgenic mice.

    Arch Virol. 2014 Jul;159(7):1849-56. doi: 10.1007/s00705-014-2099-y. Epub 2014 May 13. PMID: 24818712.

  5. 5 .

    Maie K, Fuji S, Tajima K, Tatsuno M, Yamagata S, Takahashi N, Ueda R, Hashimoto H, Takano K, Inoue Y, Ito A, Hayashi Y, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Heike Y, Yamashita T, Fukuda T.

    A higher number of infused CD34(+) cells has a positive impact on the clinical outcome after related PBSC transplantation.

    Bone Marrow Transplant. 2014 Aug;49(8):1113-5. doi: 10.1038/bmt.2014.94. Epub 2014 May 5. PMID: 24797181.

  6. 6 .

    Azuma Y, Kükenshöner T, Ma G, Yasunaga J, Imanishi M, Tanaka G, Nakase I, Maruno T, Kobayashi Y, Arndt KM, Matsuoka M, Futaki S.

    Controlling leucine-zipper partner recognition in cells through modification of a-g interactions.

    Chem Commun (Camb). 2014 Jun 18;50(48):6364-7. doi: 10.1039/c4cc00555d. PMID: 24803110.

  7. 7 .

    Takamatsu A, Abe Y, Suehiro Y, Choi I, Toyoda K, Shiratsuchi M, Uike N.

    Successful treatment with allogeneic hematopoietic stem cell transplant in a mature B-cell leukemia with MYC and BCL2 translocation.

    Leuk Lymphoma. 2014 Jul;55(7):1663-4. doi: 10.3109/10428194.2013.844342. Epub 2013 Nov 6. PMID: 24033111.

  8. 8 .

    Tanaka-Nakanishi A, Yasunaga J, Takai K, Matsuoka M.

    HTLV-1 bZIP factor suppresses apoptosis by attenuating the function of FoxO3a and altering its localization.

    Cancer Res. 2014 Jan 1;74(1):188-200. doi: 10.1158/0008-5472.CAN-13-0436. Epub 2013 Oct 31. PMID: 24177179.

  9. 9 .

    Toyoda K, Abe Y, Tsuda M, Haji S, Choi I, Suehiro Y, Kiyasu J, Ohshima K, Uike N.

    [Successful treatment with oral low-dose sobuzoxane and etoposide combined with rituximab in an elderly patient with HHV-8-negative primary effusion lymphoma-like lymphoma].

    Rinsho Ketsueki. 2014 Jul;55(7):815-9. Japanese. PMID: 25098519.

  10. 10 .

    Zhang W, Parniak MA, Mitsuya H, Sarafianos SG, Graebing PW, Rohan LC.

    Preformulation studies of EFdA, a novel nucleoside reverse transcriptase inhibitor for HIV prevention.

    Drug Dev Ind Pharm. 2014 Aug;40(8):1101-11. doi: 10.3109/03639045.2013.809535. Epub 2013 Jul 10. PMID: 23841536; PMCID: PMC4136418.

  11. 11 .

    Uike N, Choi I, Tsuda M, Haji S, Toyoda K, Suehiro Y, Abe Y, Hayashi T, Sawamoto H, Kaneko K, Shimokawa M, Nakagawa M.

    Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era.

    Int J Hematol. 2014 Oct;100(4):386-92. doi: 10.1007/s12185-014-1636-5. Epub 2014 Aug 21. PMID: 25142378.

  12. 12 .

    Matsuzawa T, Kawamura T, Ogawa Y, Maeda K, Nakata H, Moriishi K, Koyanagi Y, Gatanaga H, Shimada S, Mitsuya H.

    EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium.

    J Invest Dermatol. 2014 Apr;134(4):1158-1161. doi: 10.1038/jid.2013.467. Epub 2013 Nov 11. PMID: 24384694.

  13. 13 .

    Hayashi H, Takamune N, Nirasawa T, Aoki M, Morishita Y, Das D, Koh Y, Ghosh AK, Misumi S, Mitsuya H.

    Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.

    Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12234-9. doi: 10.1073/pnas.1400027111. Epub 2014 Aug 4. PMID: 25092296; PMCID: PMC4142999.

  14. 14 .

    Miyazaki Y, Taguchi K, Sou K, Watanabe H, Ishima Y, Miyakawa T, Mitsuya H, Fukagawa M, Otagiri M, Maruyama T.

    Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia.

    Mol Pharm. 2014 Nov 3;11(11):4238-48. doi: 10.1021/mp500453a. Epub 2014 Oct 6. PMID: 25255196.

  15. 15 .

    Ghosh AK, Schiltz GE, Rusere LN, Osswald HL, Walters DE, Amano M, Mitsuya H.

    Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.

    Org Biomol Chem. 2014 Sep 21;12(35):6842-54. doi: 10.1039/c4ob00738g. PMID: 25050776; PMCID: PMC4133278.

  16. 16 .

    Michailidis E, Huber AD, Ryan EM, Ong YT, Leslie MD, Matzek KB, Singh K, Marchand B, Hagedorn AN, Kirby KA, Rohan LC, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.

    4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.

    J Biol Chem. 2014 Aug 29;289(35):24533-48. doi: 10.1074/jbc.M114.562694. Epub 2014 Jun 26. PMID: 24970894; PMCID: PMC4148878.

  17. 17 .

    Yedidi RS, Garimella H, Aoki M, Aoki-Ogata H, Desai DV, Chang SB, Davis DA, Fyvie WS, Kaufman JD, Smith DW, Das D, Wingfield PT, Maeda K, Ghosh AK, Mitsuya H.

    A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.

    Antimicrob Agents Chemother. 2014 Jul;58(7):3679-88. doi: 10.1128/AAC.00107-14. Epub 2014 Apr 21. PMID: 24752271; PMCID: PMC4068604.

  18. 18 .

    Muftuoglu Y, Sohl CD, Mislak AC, Mitsuya H, Sarafianos SG, Anderson KS.

    Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) using pre-steady-state kinetics.

    Antiviral Res. 2014 Jun;106:1-4. doi: 10.1016/j.antiviral.2014.03.001. Epub 2014 Mar 12. PMID: 24632447; PMCID: PMC4020981.

  19. 19 .

    Yamaguchi S, Iwanaga E, Tokunaga K, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.

    IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.

    Eur J Haematol. 2014 Jun;92(6):471-7. doi: 10.1111/ejh.12271. Epub 2014 Mar 3. PMID: 24443894.

  20. 20 .

    Maeda K, Desai DV, Aoki M, Nakata H, Kodama EN, Mitsuya H.

    Delayed emergence of HIV-1 variants resistant to 4′-ethynyl-2-fluoro-2′-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.

    Antivir Ther. 2014;19(2):179-89. doi: 10.3851/IMP2697. Epub 2013 Oct 25. PMID: 24162098.

  21. 21 .

    Niederer HA, Laydon DJ, Melamed A, Elemans M, Asquith B, Matsuoka M, Bangham CR.

    HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP.

    Virol J. 2014 Sep 30;11:172. doi: 10.1186/1743-422X-11-172. PMID: 25270762; PMCID: PMC4192323.

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo@kumamoto-u.ac.jp
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.